Table 2:
Effects of 2 h, 6 h, and 24 h exposures to PCP on IL-6 mRNA levels in PBMCs
2h | Interleukin 6 mRNA expression (AU) (mean± S.D.) | ||||
---|---|---|---|---|---|
[PCP] µM |
F563 | F564 | F565 | F566 | |
0 | 46±3 | 64±6 | 30±3 | 18±0.5 | |
0.05 | 24±1* | 64±6 | 32±2 | 29±1+ | |
0.1 | 30±2* | 73±2 | 35±3 | 28±2+ | |
0.25 | 27±0.7* | 65±3 | 30±2 | 23±0.6+ | |
0.5 | 32±1* | 72±0.4 | 26±1 | 25±1+ | |
1 | 28±6* | 66±1 | 26±1 | 22±1+ | |
2.5 | 25±0.2* | 75±16 | 18±2* | 22±1+ | |
5 | 17±2* | 41±3* | 14±1* | 17±0.6 |
6h | Interleukin 6 mRNA expression (AU) (mean± S.D.) | ||||
---|---|---|---|---|---|
[PCP]
µM |
F538 | F540 | F541 | F542 | |
0 | 23±0.5 | 11±7 | 8±0.6 | 23±1 | |
0.05 | 19±0.3* | 14±3 | 45±8+ | 18±0.8* | |
0.1 | 25±0.4+ | 18±3 | 27±13 | 15±0.4* | |
0.25 | 19±0.3* | 11±0.8 | 28±3+ | 18±0.6* | |
0.5 | 24±0.2+ | 17±2 | 28±11 | 16±0.5* | |
1 | 15±1* | 16±0.4 | 36±19 | 31±2+ | |
2.5 | 12±0.1* | 22±1 | 30±8+ | 43±11 | |
5 | 18±0.3* | 12±4 | 21±2+ | 55±18 |
24h | Interleukin 6 mRNA expression (AU) (mean± S.D.) | ||||
---|---|---|---|---|---|
[PCP]
µM |
F525 | F527 | F528 | F530 | F548 |
0 | 27±2 | 15±0.1 | 5±1 | 13±1 | 9±2 |
0.05 | 21±2* | 14±1 | 19±1+ | 13±1 | 11±1 |
0.1 | 31±1+ | 15±2 | 14±3+ | 10±1* | 16±2+ |
0.25 | 39±4+ | 16±0.4+ | 11±1+ | 13±1 | 15±1+ |
0.5 | 43±3+ | 19±.1+ | 16±3+ | 10±0.4* | 10±1 |
1 | 37±1+ | 17±1 | 14±3+ | 7±0.2* | 8±.4 |
2.5 | 30±1 | 14±1 | 22±2+ | 9±3 | 9±1 |
5 | 25±8 | 11±1* | 19±3+ | 9±0.3 | 5±1* |
Values are mean±S.D. of triplicate determinations.
Indicates a significant decrease in secretion and
indicates a significant increase in secretion compared to control cells (cells treated with vehicle alone), p<0.05